SCHEMBL30925489

SCHEMBL30925489

Cc1nccnc1S(=O)(=O)Nc1cccc2cccnc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 15/20 0.67
TDP1 Q9NUW8 5/20 0.67
KMT2A Q03164 4/20 0.67
HTT P42858 2/20 0.67
AGTR1 P30556 2/20 0.67
MITF O75030 1/20 0.67
S1PR4 O95977 1/20 0.67
ALDH1A1 P00352 1/20 0.67
LMNA P02545 1/20 0.67
MAPT P10636 1/20 0.67
S1PR1 P21453 1/20 0.67
OPRK1 P41145 1/20 0.67
CKS1B P61024 1/20 0.67
SKP2 Q13309 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
GLO1 Q04760 5/20 0.64
ALOX15 P16050 1/20 0.64
MEN1 O00255 3/20 0.64
G6PD P11413 1/20 0.63
NFKBIA P25963 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214330 1.00 SLC40A1 (0.67) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL27214328 0.89 SLC40A1 (0.73) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL30925535 0.89 SLC40A1 (0.73) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL27214283 0.84 SLC40A1 (0.80) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL30925525 0.84 SLC40A1 (0.80) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL30925538 0.83 TDP1 (0.73) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL30925443 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL11973157 0.83 SLC40A1 (0.73) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL30925505 0.83 SLC40A1 (0.77) SLC40A1TDP1KMT2AHTTAGTR1
SCHEMBL27214307 0.83 TDP1 (0.73) SLC40A1TDP1KMT2AHTTAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885KMT2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.